Cargando…
Analysis and identification of the necroptosis landscape on therapy and prognosis in bladder cancer
Bladder cancer (BLCA) is one of the most common malignant tumors of the urinary system, but the current therapeutic strategy based on chemotherapy and immune checkpoint inhibitor (ICI) therapy cannot meet the treatment needs, mainly owing to the endogenous or acquired apoptotic resistance of cancer...
Autores principales: | Zhao, Zihan, Jiang, Ning, Zhang, Yulin, Bai, Yuhao, Liu, Tianyao, Li, Tianhang, Guo, Hongqian, Yang, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557096/ https://www.ncbi.nlm.nih.gov/pubmed/36246597 http://dx.doi.org/10.3389/fgene.2022.919829 |
Ejemplares similares
-
Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature
por: Li, Tianhang, et al.
Publicado: (2023) -
Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma
por: Xin, Sheng, et al.
Publicado: (2022) -
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023) -
Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer
por: Li, Tianhang, et al.
Publicado: (2022) -
p53 mutation and deletion contribute to tumor immune evasion
por: Liu, Siyang, et al.
Publicado: (2023)